This study is looking at a new way to treat deep vein thrombosis (DVT), which is a blood clot in a deep vein. It tests whether delivering dexamethasone (an anti-inflammatory medicine) around the affected vein after removing the clot helps prevent new clots and improve symptoms. The medicine is delivered using a special catheter called the Bullfrog® Micro-Infusion Device. You may be able to join if you are between 18 and 89 years old and have had DVT symptoms for up to 14 days before clot removal. The study will measure if this treatment keeps the vein open, prevents a condition called post-thrombotic syndrome (PTS), and avoids serious side effects. The study is currently unclear on its recruitment status and plans to enroll 80 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 80 participants aged 18 to 89.

What's involved

You will need to sign a consent form, follow all study procedures, complete questionnaires, and attend follow-up visits.

Compensation

Not stated in the trial record.

Follow-up

The study will follow participants for up to 24 months after the initial DVT recanalization procedure, with primary outcomes measured at 6 months and 30 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.